

Table S1 Treatment modalities and staging groups for recurrent and non-recurrent RRMS

| Variable | Subgroup | Recurrent (n=6) | Non-recurrent (n=11) | P |
|--|----------|------------------|----------------------|-------|
| Age at onset (median, IQR, months) | | 46.2 (32.8–81.3) | 62 (28.8–66.0) | 0.920 |
| Maximum tumor diameter (median, IQR, cm) | | 15.0 (7.85–18.5) | 10.1 (8.5–11.3) | 0.461 |
| IDRFs (median, IQR) | | 4 (2–4) | 2 (2–4) | 0.273 |
| Gender, n | Male | 5 | 9 | 1.000 |
| | Female | 1 | 2 | |
| Neoadjuvant chemotherapy, n | Yes | 5 | 10 | 0.596 |
| | No | 1 | 1 | |
| Visible surgical residue, n | Yes | 3 | 3 | 0.529 |
| | No | 3 | 5 | |
| Postoperative chemotherapy, n | Yes | 5 | 7 | 0.600 |
| | No | 1 | 4 | |
| Radiotherapy, n | Yes | 4 | 5 | 0.620 |
| | No | 2 | 6 | |
| TNM staging, n | 3 | 3 | 4 | 0.644 |
| | 4 | 3 | 7 | |
| IRSG Grouping, n | III | 3 | 4 | 0.619 |
| | IV | 3 | 7 | |
| Survival, n | Alive | 0 | 5 | 0.102 |
| | Death | 6 | 6 | |